IP Library Granted Patent US 7,344,841
Granted Patent B2
US 7,344,841 · App. 11/438,161 · Granted Mar 18, 2008

Real-time monitoring of nucleic acid target-identifying signals

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,344,841
App. No.
11/438,161
Granted
Mar 18, 2008
Kind
B2
Abstract

This invention provides compositions and methods for genetic testing of an organism and for correlating the results of the genetic testing with a unique marker that unambiguously identifies the organism. The markers may be internal markers, such as for example single nucleotide polymorphisms (SNPs), short tandem repeats (STRs), or other sites within a genomic locus. Alternatively, the markers may be external, such that they are separately added to the genetic sample before testing.

Claims (20)

1. A method of sequence-specific amplification of assay signals produced in the analysis of a target nucleic acid sequence, the method permitting real-time monitoring of amplified signal and comprising the following steps:

(a) providing a temperature-controlled sample containment device that permits real-time recording of optical assay signals produced within said device, and a temperature control means for controlling the temperature of said device;

(b) providing within said sample containment device a set of interrogation probes, said interrogation probes being capable of forming a hybridization complex with a target nucleic acid and being attached to beads, wherein said beads are associated with a chemically or physically distinguishable characteristic that identifies the interrogation probes attached thereto;

(c) contacting said interrogation probes with the target sequence to form a hybridization complex between the interrogation probes and the target sequence;

(d) contacting said hybridization complex with a second oligonucleotide probe, said second probe comprising a label and capable of being ligated to the interrogation probes contained within the hybridization complex;

(e) providing conditions suitable for ligating said second labeled oligonucleotide probe to the interrogation probe;

(f) detecting the optical signals from the second labeled probes; and

(g) performing one or more annealing-ligating-detecting-denaturing cycles, each cycle increasing the number of ligated probes in arithmetic progression and involving the following steps:

(i) providing a first temperature for the formation of the hybridization complex;

(ii) providing a second temperature for ligase-catalyzed ligation of the interrogation probe and the second labeled probe to occur to thereby generate a ligation product, wherein ligation is associated with a change in optical signature of beads associated with the ligation product;

(iii) imaging and/or recording optical signals from the ligation product thereby permitting real-time monitoring of amplified signal emanating from the ligation product; and

(iv) providing a third temperature for denaturing all hybridization complexes.

2. The method of claim 1 wherein steps (c) to (g) are repeated one or more times.

3. The composition of claim 1 wherein the target nucleic acid sequences are derived from the patient genomic sample by amplification of one or more nucleic acid subsequences within the patient genomic sample.

4. The composition of claim 3 wherein the amplification is performed using the polymerase chain reaction.

5. The method of claim 1 , wherein the target nucleic acid sequence includes a mutation site or a polymorphic site and said set interrogation probes includes members designed to detect the different nucleotides at the mutation or polymorphic site.

6. The method of claim 1 , wherein the target sequence includes a mutation site or a polymorphic site and the set of interrogation probes includes members capable of annealing to subsequences in the target sequence including the mutation site or the polymorphic site, within a range of proximity to the mutation site or the polymorphic site.

7. The method of claims 5 or 6 , wherein the polymorphic site is a single nucleotide polymorphism.

8. The method of claims 5 or 6 , wherein the polymorphic site is a short term tandem repeat site.

9. The method of claim 1 wherein the label is an inorganic nanoparticle label, including semiconductor Quantum Dot particles and Resonant Light Scattering metal nanoparticles.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Mar 15, 2023
From: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
To: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS, INC.
Reel/Frame 063090/0033 →
RELEASE OF SECURITY INTEREST Recorded Mar 15, 2023
From: ALTER DOMUS (US) LLC, AS COLLATERAL AGENT
To: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS, INC.
Reel/Frame 063090/0111 →
RELEASE OF PATENT SECURITY INTERESTS Recorded Jul 2, 2020
From: CITIBANK, N.A.
To: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; IMMUCOR GTI DIAGNOSTICS, INC.; SIRONA GENONICS, INC.
Reel/Frame 053121/0935 →
SECURITY INTEREST Recorded Jul 2, 2020
From: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS INC.
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 053119/0135 →
SECURITY INTEREST Recorded Jul 2, 2020
From: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS INC.
To: ALTER DOMUS (US) LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 053119/0152 →
PATENT SECURITY AGREEMENT Recorded Aug 19, 2011
From: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.
To: CITIBANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 026778/0640 →